# Hepatitis C Virus(HCV) Heart and Lung Study

> **NCT02858180** · PHASE4 · COMPLETED · sponsor: **Duke University** · enrollment: 15 (actual)

## Conditions studied

- Hepatitis C, Chronic
- Heart Failure
- Pulmonary Disease, Chronic Obstructive
- Lung Diseases, Interstitial

## Interventions

- **DRUG:** Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)

## Key facts

- **NCT ID:** NCT02858180
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2019-04-11
- **Final completion:** 2019-07-04
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02858180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02858180, "Hepatitis C Virus(HCV) Heart and Lung Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02858180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*